Improving Single Donor Success Rate in Clinical Islet Transplantation Using Alpha-1 Antitrypsin (Aralast NP)

Trial Profile

Improving Single Donor Success Rate in Clinical Islet Transplantation Using Alpha-1 Antitrypsin (Aralast NP)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 May 2017

At a glance

  • Drugs Alpha 1-antitrypsin (Primary)
  • Indications Transplant rejection; Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 May 2017 Planned End Date changed from 1 Mar 2018 to 1 Mar 2020.
    • 01 May 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top